Myositis and myasteniform syndrome related to pembrolizumab

This case report concerns a 63-year-old man affected by metastatic undifferentiated liposarcoma. After receiving pembrolizumab as a second-line treatment in a clinical trial, the patient experienced an immune-mediated myocarditis, myositis and myasteniform syndrome. The last two adverse events showe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMJ Case Rep
Glavni autori: Sanchez-Sancho, Pablo, Selva-O'Callaghan, Albert, Trallero-Araguás, Ernesto, Ros, Javier, Montoro, Bruno
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8296758/
https://ncbi.nlm.nih.gov/pubmed/34290006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-241766
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items